Tuesday, September 8, 2026
← Back to archivePolicy
Policy•STAT News•Sep 8, 2026
Hospitals pursue deals to ensure survival as Trump’s Medicaid cuts loom
background ▾
- •Rural hospital merger activity has accelerated following Trump's Medicaid cuts, with merger brokers reporting scores of deals in discussion beyond those publicly announced
- •Consolidation provides smaller hospitals access to drug discount programs, residency funding, and tax-exempt status arguments, but risks reducing service availability in remote regions if larger systems optimize care locations
- •Certain regions—particularly highly rural areas with high Medicaid dependence—lack larger systems willing or able to acquire struggling hospitals, creating a two-tier consolidation outcome
Our Lady of the Angels HospitalFMOL HealthNorth Star Health Alliance
→ Read original articlePolicy•KFF•Sep 8, 2026
AI’s Role in Health Care: What Keeps You Up at Night?
background ▾
- •Key AI concerns in healthcare include deepfakes, misinformation, bias, and loss of human connection in patient care
Policy•STAT News•Sep 8, 2026
Reynolds is selling fruity new vapes unauthorized by FDA
background ▾
- •Reynolds is commercially selling completely unauthorized fruit-flavored vapes in violation of U.S. law, relying on the FDA's May 2024 enforcement discretion guidance that permits sales pending authorization if certain conditions are met
- •The FDA's policy shift occurred within a week of Reynolds' $5 million donation to a Trump super PAC and reported White House discussions about e-cigarette regulation, raising questions about political influence on tobacco product enforcement
- •Monitor whether other major manufacturers follow Reynolds' strategy of launching unauthorized products ahead of FDA authorization, potentially triggering broader market noncompliance and regulatory collapse in the e-cigarette category
Reynolds AmericanBritish American TobaccoR.J. Reynolds Vapor CompanyVuse Pro
→ Read original articlePolicy•STAT News•Sep 8, 2026
Opinion: It’s time to take the gloves off during vaccination
background ▾
- •This is an opinion/advocacy piece with no new clinical data, policy change, or industry event—it represents a perspective call for practice change rather than reporting on actionable developments affecting pharma or biotech companies.
Policy•STAT News•Sep 8, 2026
Opinion: I’m a fat medical student. I refuse to let myself be shamed for it
background ▾
- •Weight bias and stigma are documented and pervasive within medical education and clinical practice, potentially affecting admissions, peer treatment, and clinical decision-making
Market Access
Market Access•STAT News•Sep 8, 2026
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
background ▾
- •FDA approval of Rasonque triggered immediate closure of the expanded access program, creating a gap between program closure and commercial insurance coverage availability that can stretch weeks to months—time pancreatic cancer patients do not have.
- •Pharmacy benefit managers and Medicare Part D are experiencing administrative delays and erroneous denials citing non-clinical regulatory justifications, requiring individual physician intervention to resolve coverage denials.
- •This case exposes a coordination failure between regulatory approval timelines and payer coverage processes that particularly impacts aggressive cancers; watch for whether this prompts FDA or CMS policy changes around transition procedures for expanded access programs.
Revolution MedicinesOptumRxBridgeBio Oncology TherapeuticsRasonquesotorasibFOLFIRINOX
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 8, 2026
Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
background ▾
- •Del-desiran, valued at up to $6B peak sales, failed primary endpoint in phase 3 Harbor trial—a critical validation test for the $12B Avidity acquisition
- •Novartis is 1-for-3 on major late-stage readouts in H2 2026, raising broader questions about pipeline credibility and near-term growth prospects beyond 2030
- •Watch for regulatory guidance discussions and whether secondary/exploratory endpoint data can salvage development path; Novartis also has two other Avidity assets (delpacibart programs) that may partially offset this loss
NovartisAvidity Biosciencesdel-desiranRhapsidopelacarsen
→ Read original articleClinical Trials•Endpoints News•Sep 8, 2026
#ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer
background ▾
- •Roivant's inhaled ILD candidate met primary Phase 2 efficacy endpoints, exceeding investor consensus expectations
- •The asset originated from Bayer, demonstrating Roivant's ability to advance partnered/acquired programs through clinical development
- •Phase 3 progression likely; regulatory approval timeline and competitive positioning against other ILD therapies warrant monitoring
Roivant SciencesBayerRoivant inhaled ILD candidate (INN/brand name not specified in article)
→ Read original articleClinical Trials•Endpoints News•Sep 8, 2026
#ERS26: Beam says AATD base editing data hold up after one year
background ▾
- •Beam's base editing therapy for AATD shows durable efficacy at one year, validating the therapeutic approach in this rare genetic disease
- •Early-stage data durability is encouraging but does not yet establish clinical significance or regulatory path to approval
Beam Therapeuticsbase editing gene therapy (AATD indication, development stage)
→ Read original articleClinical Trials•Endpoints News•Sep 8, 2026
Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
background ▾
- •Novartis faces dual major clinical trial failures in rapid succession, signaling potential systemic issues with pipeline execution or asset quality assessment
- •The Avidity-acquired asset failure suggests risk in the company's M&A integration and due diligence processes
- •Investor confidence and stock valuation face pressure; watch for management commentary on remaining pipeline prioritization and potential strategic pivots
NovartisAvidity
→ Read original articleClinical Trials•Endpoints News•Sep 7, 2026
Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly
background ▾
- •Novartis pelacarsen Phase 3 failure represents a third consecutive major cardio outcomes trial setback in big pharma within two months, raising class-level questions about Lp(a)-lowering strategies
- •Amgen and Eli Lilly's competing Lp(a) programs now face heightened scrutiny and regulatory uncertainty given the accumulating negative data
- •Watch for upcoming trial results from Amgen (MRKx594/MK-0616) and Lilly programs, as well as any pivots in development strategy or mechanistic explanations from Novartis
NovartisAmgenEli Lillypelacarsen
→ Read original article